What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2025-03-03 compared with 2024-02-29 · 216 added, 170 removed, 371 unchanged (51% of the section changed)

2 unchanged sentences

Many of our products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples.

Our products and solutions address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research.

Our technology platforms include magnetic resonance technologies, mass spectrometry technologies, gas and liquid chromatography, triple quadrupole mass spectrometry technologies, X-ray technologies, spark-optical emission spectroscopy, atomic force microscopy, stylus and optical metrology technology, fluorescence optical microscopy, and infrared and Raman molecular spectroscopy technologies.

Our product portfolio also includes testing solutions used in microbiology and infectious disease diagnostics, including our MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips and fluorescence-based polymerase chain reaction (PCR) technology for selected infectious disease applications.

We develop, manufacture and distribute a range of field analytical systems for chemical, biological, radiological, nuclear and explosives, or CBRNE detection.

We also develop, manufacture and market low temperature superconducting materials and devices based primarily on metallic low temperature superconductors.

Our products and solutions address the rapidly evolving needs of a diverse array of customers in life and materials science research, biopharmaceuticals, applied markets, microbiology, in-vitro diagnostics, and nanotechnology.

Our technology platforms include magnetic resonance, mass spectrometry, gas and liquid chromatography, X-ray, microscopy, metrology, and molecular spectroscopy technologies.

Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research and offers differentiated, high value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.

Our corporate headquarters are located in Billerica, Massachusetts.

We maintain major technical and manufacturing centers in Europe, North America and Southeast Asia, and have sales offices located throughout the world.

We maintain major technical and manufacturing centers in Europe and North America, and have sales offices located throughout the world.

Business Segments

We have four reportable segments, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST).

We have four reportable segments, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection), BSI NANO, and Bruker Energy & Supercon Technologies (BEST).

Our products, which have particular application in structural proteomics, drug discovery, pharmaceutical and biotechnology research and production, and the food and materials science fields, provide customers with the ability to determine the structure, dynamics, and function of specific molecules, such as proteins, and thus allows them to understand fundamental biological processes including the formation and progression of diseases.

Furthermore, BSI BioSpin’s product enables the characterization of mixtures and also complex materials, rendering them high value-added tools for a variety of industrial applications.

BSI BioSpin Segment

The BSI BioSpin Segment comprises the Bruker Magnetic Resonance, Applied Industrial and Clinical, Preclinical Imaging and Service and Lifecycle Support and Integrated Data Solution Divisions.

BSI BioSpin designs, manufactures and distributes enabling life science tools based on magnetic resonance technology.

The BSI BioSpin Segment comprises the following divisions:

• Magnetic Resonance Spectroscopy:

Offers innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products, ranging from benchtop to ultra-high field systems.

Magnetic resonance is a natural phenomenon occurring when a molecule placed in a magnetic field emits a signature radio frequency.

The signature radio frequency is characteristic of the particular molecule and provides a multitude of precise chemical and structural information.

Depending on the intended application, we market and sell to our customers an NMR system or an EPR system (each as defined below).

BSI BioSpin also manufactures and sells single and multiple modality systems using MRI, PET, SPECT, CT and MPI Technologies (each as defined below).

BSI BioSpin’s products, which have particular application in structural proteomics, drug discovery, pharmaceutical and biotechnology research and production, and the food and materials science fields, provide customers with the ability to determine the structure, dynamics, and function of specific molecules, such as proteins, and thus allows them to understand fundamental biological processes including the formation and progression of diseases.

Furthermore, BSI BioSpin’s product enables the characterization of mixtures and also complex materials, rendering them high value-added tools for a variety of industrial applications.

BSI BioSpin also develops system agnostic software solutions.

Software offerings include analytical instrumentation and data management support for life sciences and other industries to accelerate research, product development and process optimization.

• Preclinical Imaging:

Manufactures and markets solutions for in-vivo processes and drug discovery in fields including oncology, neurology, cardiology, inflammation, infectious diseases, cancer research, functional and anatomical neuroimaging, orthopedics, cardiac imaging, and stroke models.

Our imaging portfolio includes single and multiple modality solutions using MRI, PET, SPECT, CT and MPI Technologies (each as defined below).

• Biopharma and Applied:

Focuses on innovative solutions for emerging and applied market segments and markets comprehensive services across the entire value chain, from raw materials to finished products, and from innovation to disease prevention in pharma-biotech, cleantech, industrial, and other applied markets, as well as in the clinical market.

• Services and Lifecycle Support:

Dedicated to delivering service and aftermarket solutions that complement our advanced instruments.

• Integrated Data Solution:

Accelerates scientific results by automating and digitizing workflows.

The vendor-agnostic platform integrates across laboratory and manufacturing ecosystems, supporting digital transformation.

It offers comprehensive software solutions for workflow integration, automation, and artificial intelligence readiness, adhering to Findability, Accessibility, Interoperability, and Reusability (FAIR) data principles.

• Automation:

Provides solutions for lab automation and digitalization in Research & Development and Quality Control.

The vendor-agnostic automation complements Bruker BioSpin’s platforms in the pharma-biotech, cleantech, industrial, and other applied markets by automating and digitally transforming laboratories.

The majority of BSI BioSpin’s customers are academic and government research facilities.

Other customers include pharmaceutical and biotechnology companies;

chemical, food and beverage, clinical and polymer companies;

battery, chemical, food and beverage, clinical and polymer companies;

and nonprofit laboratories.

We continued to enable access to our high-performance GHz NMR technology.

Four additional GHz NMR systems, representing the top end of our portfolio, were accepted by our customers (two 1.2 GHz, one 1.1 GHz, and one 1.0 GHz).

This was supported by the launch of a unique single-story 1.0 GHz system that significantly reduces footprint, weight, and ceiling height requirements and cuts liquid helium consumption by two-thirds.

In the applied markets, we made significant progress with our new solutions that are built on the benchtop Fourier NMR platform, such as reaction monitoring in chemical and pharmaceutical research as well as GxP solutions for quality control in manufacturing.

In our clinical segment, we launched an NMR assay for Research Use Only for molecular phenomics research on blood samples from ‘Long COVID’ patients.

In addition, the introduction of the new MRI portfolio for preclinical imaging markets eliminates the need for liquid helium or nitrogen refills while providing high field sensitivity and resolution for advanced MRI and PET/MR research.

During 2024, we continued our focus on accelerating growth, enhancing customer relationships, and driving innovation with our key initiatives, which include expanding into high-potential markets, leveraging core strengths, and driving recurring revenue through aftermarket and connected services.

With three additional successful installations of 1.2 GHz NMR systems, we continue to advance ultra-high field access, supporting studies in structural biology, pharmacology, and cellular biology, aligning with Bruker's mission to provide cutting-edge technology for scientific research.

Furthermore, during 2024, we completed our acquisition of Spectral Instruments Imaging and Chemspeed Technologies AG, and the minority investment in NovAliX, which align with the segment's goals of expanding its technological capabilities, entering new markets, and enhancing its product portfolio.

The acquisition of Spectral Instruments Imaging, a leader in preclinical in-vivo optical imaging systems, augments in the technology and product portfolio of the Bruker BioSpin Preclinical Imaging division, broadening its range of preclinical solutions for disease research.

Additionally, the acquisition of Chemspeed Technologies AG provides us entry into lab automation and digitalization, complementing our existing product platform of vendor-agnostic solutions.

Through the minority investment in NovAliX, we have taken a step into the preclinical Contract Research Organization (CRO) space, specializing in drug discovery services.

This partnership aims to advance our expertise in structural biology and biophysics.

BSI BioSpin Segment’s instruments are based on the following technology platforms:

6 unchanged sentences

• CT —Computed tomography;

• Automation —Flexible lab automation solutions;

• Software —Comprehensive data management suite.

NMR is a qualitative and quantitative analytical technique that is used to determine the molecular structure and purity of a sample.

18 unchanged sentences

Annihilation of the positron produces two photons which show an angle of 180° between them, distinguishing these photons from photons originating from other sources.

The PET tracer enriches in certain regions of interest within the body and gains molecular information from the animal in vivo .

The PET tracer enriches in certain regions of interest within the body and gains

molecular information from the animal in vivo .

This has widespread applications, most importantly for oncology, inflammation, neurology and cardiovascular disorders, as well as metabolic disease, drug discovery and bone disease.

6 unchanged sentences

CT is being used in a wide range of preclinical investigations in the fields of bone-orthopedics, cardiology, pulmonology, oncology and metabolism among others.

The Automation portfolio offers platforms and digital tools for research and development and quality control labs, supporting various applications including synthesis, NMR, XRD, and IR.

These solutions are designed for scalability, modularity, and flexibility, enhancing lab connectivity, saving time and costs, and boosting outcomes.

Rooted in scientific expertise, the technology provides compliance-ready and configurable systems to fit exact workflows.

The comprehensive Software suite of data management solutions is designed to facilitate digitalization and readiness for artificial intelligence and automation.

It includes tools for experiment design, data analysis, and process management, enabling real-time understanding, monitoring, and control of processes.

Additionally, it integrates robotics and automation technologies to provide transformative solutions, supporting the automation and digitalization of labs and factories under a unified platform.

The BSI BioSpin Segment also offers a range of services, product lifecycle support, scientific software and workflow solutions to customers who use BSI BioSpin products.

BSI CALID Segment

The BSI CALID Segment comprises the Bruker Life Sciences Mass Spectrometry, Bruker Applied Mass Spectrometry, Bruker Microbiology and Diagnostics and Bruker Optics Divisions.

The Bruker Life Sciences Mass Spectrometry primarily designs, manufactures and distributes life science mass spectrometry, or MS, instruments that can be integrated and used along with sample preparation or chromatography instruments to design an analytical workflow and mass spectrometry-based solutions including informatics software.

The BSI CALID Segment comprises the following Divisions:

• Bruker Life Sciences Mass Spectrometry:

Primarily designs, manufactures and distributes life science mass spectrometry, or MS, instruments that can be integrated and used along with sample preparation or chromatography instruments to design an analytical workflow and mass spectrometry-based solutions including informatics software.

Bruker Life Science Mass Spectrometry products are used in research, pharmaceutical and biotechnology development.

Bruker Applied Mass Spectrometry primarily designs solutions based on mass spectrometry for the food, environmental, forensics, clinical research, and industrial markets.

• Bruker Applied Mass Spectrometry:

Primarily designs solutions based on mass spectrometry for the food, environmental, forensics, clinical research, and industrial markets.

Analytical areas such as toxicology, safety, authenticity, adulteration, quality control of starting and finished goods are amongst the applications covered and are used across industrial, government and academic institutes.

Mass spectrometers are sophisticated devices that measure the mass or weight of a molecule and can provide accurate information on the identity, quantity and primary structure of the molecule.

Mass spectrometry-based solutions often combine advanced mass spectrometry instrumentation, automated sampling and sample preparation robots, reagent kits and other disposable products used in conducting tests, or assays, and bioinformatics software.

We offer mass spectrometry systems and integrated solutions for applications in multiple existing and emerging life science markets and chemical and applied markets, including expression proteomics, clinical proteomics research, metabolic and peptide, lipid or glycan biomarker profiling, drug discovery and development, molecular diagnostics research and molecular and systems biology, as well as basic molecular medicine research.

The Bruker Microbiology and Diagnostics Division develops, manufactures and distributes innovative solutions for microbial identification, antibiotic resistance and susceptibility testing, polymerase chain reaction (PCR) based molecular diagnostic solutions for culture-free infectious disease diagnostics, as well as monoclonal antibodies and recombinant proteins as raw materials for diagnostic assays.

Bruker Microbiology and Diagnostics solutions are used primarily in the human and veterinary clinical diagnostic, food microbiology and pharma microbiology settings.

Our MALDI Biotyper mass spectrometry solution and test kits, DNA test strips and fluorescence-based PCR technologies are designed for in-vitro diagnostic (IVD) use in clinical microbiology markets in certain configurations and certain countries, where regulatory approvals have been achieved.

In addition to culture-based microbial identification with the MALDI Biotyper platform, the Genotype and Fluorotype molecular diagnostics (MDx) kits enable a culture-free detection and analysis of microbes and viruses directly from patient samples with a special focus on tuberculosis, HIV viral load, viral hepatitis and sexually transmitted diseases.

Mass spectrometers are sophisticated devices that measure the mass or weight of a molecule, and with the addition of trapped ion mobility spectrometry (TIMS) and collision cross section (CCS), can provide accurate information on the identity, quantity, and primary structure of a molecule.

We offer advanced mass spectrometry solutions combining automated robotics for sample preparation and handling, reagent kits and other disposable products used in conducting tests, or assays, with applications specific software packages.

• Bruker Microbiology and Infection Diagnostics:

Develops, manufactures and distributes innovative solutions for microbial identification, antibiotic resistance and susceptibility testing, polymerase chain reaction (PCR) based molecular diagnostic solutions for culture-free infectious disease diagnostics, histology, cellular staining, osmolarity testing as well as monoclonal antibodies and recombinant proteins as raw materials for diagnostic assays.

Bruker Microbiology and Diagnostics solutions are used primarily in clinical microbiology, food microbiology, pharma microbiology, veterinary medicine and infectious disease testing.

In accordance with the respective market segments the products are either labeled for in-vitro diagnostic (IVD) use, general purpose (GP) or research-use only (RUO).

Our mass spectrometry solution and test kits, DNA test strips and fluorescence-based PCR technologies are designed for IVD use in clinical microbiology markets in certain configurations and certain countries, where regulatory approvals have been achieved.

Our Genotype and Fluorotype molecular diagnostics (MDx) kits enable a culture-free detection and analysis of microbes and viruses directly from patient samples with a special focus on tuberculosis, HIV viral load, viral hepatitis and sexually transmitted diseases.

Molecular Diagnostics utilize PCR assays and systems to provide diagnostic solutions for a number of different disease states, including respiratory, mycobacteria (including tuberculosis), virology, safety of immunocompromised patients, sexually transmitted infections, gastroenteric diseases as well as other microbiology tests.

Depending on the assay being used, the technology enables users to ascertain basic identification of a certain infection, distinguish infections which can cause similar symptoms and detect specific microbial resistance, all from a single sample.

The GenoType portfolio has been established for over 30 years and has been successful in mycobacteria and tuberculosis detection, differentiation, and identification of antibiotic resistance markers.

The portfolio now includes FluoroType ® , using fluorescence-based real-time PCR technology, and more recently we have also developed LiquidArray ® assays based on melt curve analysis for optimized asymmetrical PCR technology.

LiquidArray ® uses light-on-off probes, providing a powerful technology to identify a broad number of indicators for different infections or resistance markers from a single sample, providing greater depth of information.

We are applying this approach to a new portfolio of syndromic panels for the diagnostics of sexually transmitted diseases and gastro-intestinal diseases.

As a producer of extraction chemistry and instrumentation alongside integrated thermocyclers, software and a range of assays, Bruker brings complete diagnostic solutions to the Molecular Diagnostics market.

The Bruker Optics Division primarily designs, manufactures and distributes research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy and imaging technologies.

Our portfolio includes FluoroType ® , using fluorescence-based real-time PCR technology, and more recently we have also developed LiquidArray ® assays based on melt curve analysis for optimized asymmetrical PCR technology.

LiquidArray ® uses light-on-off probes, providing a powerful technology to identify a broad number of indicators for different infections or

resistance markers from a single sample, providing greater depth of information.

Following the acquisition of ELITechGroup, our portfolio now includes InGenius and BeGenius systems which are integrated Sample-to-Answer PCR systems that perform automated nucleic acid extraction, specific PCR reaction and data interpretation without user interaction.

• Bruker Optics:

Primarily designs, manufactures and distributes research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy and imaging technologies.

These products are utilized in industry, government and academia for a wide range of applications and solutions for life science, pharmaceutical, food and agricultural analysis, quality control and process analysis applications.

Infrared and Raman spectroscopies are widely used in both research and industry as simple, rapid, nondestructive and reliable techniques for applications ranging from basic sample identification and quality control to advanced research and also in remote sensing setups for environmental control.

The technologies and instruments of the division are also used for military and civil purposes in the field of detection of chemical, biological, radioactive, nuclear substances and explosives (CBRNE).

The Bruker Optics Division also utilizes Fourier transform and dispersive Raman measurement techniques on an extensive range of laboratory and process spectrometers.

1 unchanged sentence

Customers of our BSI CALID Segment include pharmaceutical, biotechnology and diagnostics companies, contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensic laboratories, agriculture, food and beverage safety, environmental and clinical microbiology laboratories, hospitals, and government departments and agencies.

The Bruker LSMS Division has launched a number of new mass spectrometry-based solutions and additional workflows, including the timsTOF Ultra mass spectrometer, the evolution of our timsTOF SCP, enabling researchers to analyze proteins from even sub-single cell amounts allowing for increased throughput in immunopeptidomic workflows while also increasing linear dynamic range.

The microGRID capability for the timsTOF flex and MALDI-2 platforms allowing 5 um spatial resolution for tissue imaging.

In tissue, protein analysis using MALDI Imaging applications were enhanced by the launch of the MALDI Hi-Plex Immunohistochemistry (IHC) labels that can potentially allow for multiplexing hundreds of proteins in a single MALDI-TOF analysis.

The photocleavable mass tag approach used in the HiPlex IHC technique are uniquely formulated for high-sensitivity MALDI mass spectrometry analysis.

In 2022, Prolab AG was acquired, a Swiss-based, microfluidics components manufacturer whose components are an integral part of the nanoElute nanoflow LC system and PepSep, a nanocolumns manufacturer to augment the proteomics workflow for the timsTOF platform.

This was further augmented by the 2022 acquisition of PreOmics, a company specializing in sample preparation with their iST-workflow for efficient and automatable sample clean-up as well as the beatbox enabling easy-to-use tissue lysis.

The 2023 acquisition of the Swiss-based Biognosys AG further enhances the post-processing portfolio with their industry leading software Spectronaut for DIA data analysis as well as granting access to important quality control tools like the iRT Kits, rounding out the workflow options from sample preparation until final data processing and interpretation.

In 2023 Fasmatech was acquired gaining an additional R&D site in Athens as well as access to the Omnitrap technology allowing research into addition fragmentation methods.

Since its launch in 2016, the timsTOF has evolved into six variants, namely the Pro 2, the HT, the SCP, the Ultra, the fleX and the fleX MALDI-2 platforms which showcases the power of trapped ion mobility for life sciences applications such as multiomics, tissue imaging, single cell analysis and immunopeptidomics.

In 2023, the newly formed BAMS Division, launched its first dedicated solution based on the EVOQ DART TQ+ which focused on driving chromatography-free mass spectrometry as a faster and greener analytical innovation to move away from lengthy chromatographic methods.

One of the initial key strategies centers on addressing the clinical and forensic toxicology market in the USA, aided by the acquisition of PinPoint with their ToxBox technology.

In our microbiology and molecular diagnostics markets, we introduced the MALDI Biotyper Sirius broadly into the market.

In our molecular diagnostics portfolio, we launched two assays in the field of respiratory disease testing, primarily covering SARS-CoV 2 testing for the diagnosis of COVID-19 infection.

The Fluorotyper-SARS-CoV 2 plus kit allows for a real-time PCR detection of the SARS-CoV 2 virus.

It detects two viral genes in parallel as a mechanism for high sensitivity.

The additional FluoroType ® SARS-CoV-2/Flu/RSV assay is a multiplex real-time PCR kit that detects four viruses of clinical significance causing respiratory disease during the winter season:

SARS-CoV 2, influenza A, influenza B and respiratory syncytial virus (RSV).

Our Bruker Optics division launched LUMOS II during 2020, a fully automated stand-alone FTIR imaging microscope.

LUMOS II provides ultrafast FTIR imaging capabilities based on modern focal plane array (FPA) detector technology.

The novel LUMOS II is designed to identify particles, to determine coatings and contamination, and to reveal the polymeric composition of plastics.

During 2022, the Bruker Optics division launched HYPERION II with QCL microscopy (ILIM) as the leading IR microscope, which provides IR imaging down to the diffraction limit.

HYPERION II ILIM combines FT-IR and Infrared Laser Imaging microscopy for the first time in a single device, offering all three measurement modes:

transmission, reflection, and ATR.

With Hyperion II ILIM users can access an IR microscope that combines FT-IR and QCL technology in one instrument.

During 2023 the Bruker Optics division launched Mobile IR II, a mobile FT-IR spectrometer with laboratory performance, and Matrix-F II, a dedicated FT-NIR process spectrometer.

Mobile IR II is one of the only portable FT-IR spectrometers with true lab-grade spectral performance.

MATRIX-F II is the only FT-NIR spectrometer which can measure material in contact as well as contactless with just one instrument using light fiber technology.

It allows direct measurements in process reactors and pipelines, leading to a better understanding and control of the process.

During 2024, we continued our focus on accelerating growth, enhancing customer relationships, and driving innovation through the launch of our new NIR-spectrometer BEAM, the first dedicated single-point spectrometer utilizing the full power of FT-NIR spectroscopy as well as introducing our next-generation version of its Multi-Purpose Analyzer (MPA-III).

We also introduced several other new technologies and workflows such as Novor V2.0, a machine learning algorithm trained on HLA peptides for immunopeptidomics;

TwinScape a cloud-based liquid chromatography and mass spectrometry quality control application;

lyco-PASEF® a glycopeptide analysis mode;

a discovery service for deep plasma proteomics, with optional integration of Alamar Bio's NULISA® panels for inflammation and CNS studies;

and we released the neoFLEX benchtop MALDI TOF for spatial biology application and the timsTOF Ultra 2 mass spectrometer, with enhanced sensitivity for low input and single cell applications.

Furthermore, during 2024, we completed our acquisition of Tornado Spectral Systems Inc.

(Toronto, Canada), Nanophoton Corporation (Osaka, Japan), Dynamic Biosensors GmbH (Munich, Germany and Massachusetts, U.S.A.) as well as ELITechGroup in various locations.

The acquisition of Tornado Spectral Systems Inc., a Canadian company specializing in process Raman instruments, complemented the segments Raman spectrometers products with its patented High-Throughput Virtual Slit (HTVS) technology and Raman analyzers such as the HyperFlux PRO Plus, Process Guardian and SuperFlux for more accurate chemical identification and quantification in mixtures and at low concentrations.

The acquisition of Nanophoton Corporation augmented our Bruker Optics division with its broad portfolio of advanced Raman microscopes, capable of reducing measurement time by several hundred times and employing a unique beam-scanning method based on stochastic process and information theories.

The acquisition of Dynamic Biosensors GmbH expanded our biophysical analytics portfolio including measurement of molecular interactions and kinetics.

The acquisition of ELITechGroup which is active in the molecular diagnostics, microbiology and biomedical testing equipment field, complemented the segments MALDI BioTyper® platform for bacterial and fungal identification and establish Bruker as an innovative and growing infectious disease specialist in the IVD market.

The BSI CALID Segment’s instruments are based on the following technology platforms:

3 unchanged sentences

• ITMS —Ion trap mass spectrometry;

• IMS – Ion mobility spectrometry;

• GC-MS —Gas chromatography-mass spectrometry systems utilizing triple-quadrupole time-of-flight mass spectrometry;

3 unchanged sentences

• PCR —Polymerase chain reaction;

• Raman —Raman spectroscopy.

• Raman —Raman spectroscopy and microscopy, and

• QCL IR – Quantum Cascade LASER Infrared spectroscopy and microscopy.

MALDI-TOF mass spectrometers utilize an ionization process to analyze solid samples using a laser that combines high sample throughput with high mass range and sensitivity.

11 unchanged sentences

ESI-TOF mass spectrometers utilize an electrospray ionization process to analyze liquid samples.

This ionization process, which does not dissociate the molecules, allows for rapid data acquisition and analysis of large biological molecules.

This ionization process, which does not dissociate the molecules, allows for rapid data acquisition and analysis of large biological molecules as well as complex biosamples.

ESI-TOF mass spectrometers are particularly useful for:

12 unchanged sentences

We offer next-generation hybrid MRMS systems that combine a traditional external quadrupole mass selector and hexapole collision cell with a high-performance MRMS for further ion dissociation, top-down proteomics tools and ultra high-resolution detection.

IMS systems utilize Ion-mobility spectrometry (IMS) is an analytical technique used to separate and identify ionized molecules in the gas phase based on their mobility in a carrier buffer gas.

Though heavily employed for military or security purposes, such as detecting chemical warfare agents and explosives (explosive trace detection, ETD), the technique also has many laboratory and analytical applications.

ITMS systems collect all ions simultaneously, which improves sensitivity relative to previous quadrupole mass spectrometers.

25 unchanged sentences

The technique also has applications in life sciences, forensics and artwork authentication.

QCL IR spectroscopy utilizes a different source for generating Infrared (IR) light, which is a quantum cascade LASER which constitutes a tunable (mid-)IR LASER.

Quantum cascade lasers are fundamentally different from the conventional thermal sources which are used for FT-IR.

QCL exhibits a spectral power density which is typically orders of magnitudes higher than that of a thermal source, therefore providing advantages in terms of applicability of samples and speed of measurement particularly for microscopy or imaging experiments.

This technique is applied in life sciences, forensics, semiconductor industries and others.

Additionally, the Bruker Detection product line offers a wide range of portable analytical and bioanalytical detection systems and related products for CBRNE detection.

3 unchanged sentences

BSI NANO Segment

The BSI Nano Segment comprises the Bruker AXS, Bruker Nano Analytics, Bruker Nano Surfaces and Metrology divisions, Consolidated Fluorescence Microscopy, Canopy Biosciences and Acuity Business Units.

The Bruker AXS Division designs, manufactures and distributes advanced X-ray instruments that use electromagnetic radiation with extremely short wavelengths to determine the characteristics of matter and the three-dimensional structure of molecules.

The BSI NANO Segment comprises of the following:

• The Bruker AXS Division :

Designs, manufactures and distributes advanced X-ray instruments that use electromagnetic radiation with extremely short wavelengths to determine the characteristics of matter and the three-dimensional structure of molecules.

This includes a product portfolio of instruments based on X-ray fluorescence spectroscopy (XRF), X-ray diffraction (XRD) and X-ray micro computed tomography (µCT), or X-ray microscopy, as well as spark optical emission spectroscopy systems (S-OES) used to analyze the concentration of elements in metallic samples.

The Bruker Nano Analytics Division manufactures and markets analytical tools for electron microscopes, including energy-dispersive X-ray spectrometers (EDS), electron backscatter diffraction systems (EBSD) and µCT accessories, as well as mobile and bench top micro X-ray fluorescence (µXRF), total reflection X-ray fluorescence spectrometers (TXRF) and handheld, portable and mobile X-ray fluorescence (HMP-XRF) spectrometry instruments.

The Bruker Nano Surfaces and Metrology Division’s products include atomic force microscopy instrumentation (AFM).

• The Bruker Nano Analytics Division:

Manufactures and markets analytical tools for electron microscopes, including energy-dispersive X-ray spectrometers (EDS), electron backscatter diffraction systems (EBSD) and µCT accessories, as well as mobile and bench top micro X-ray fluorescence (µXRF), total reflection X-ray fluorescence spectrometers (TXRF) and handheld, portable and mobile X-ray fluorescence (HMP-XRF) spectrometry instruments.

• The Bruker Nano Surfaces and Metrology Division:

This division's products include atomic force microscopy instrumentation (AFM).

Such instruments provide atomic or near atomic resolution of surface topography and nanoscale, mechanical, electrical and chemical information using nano scale probes.

1 unchanged sentence

In addition, the division manufacturers and markets automated X-ray metrology, automated AFM defect-detection and photomask repair and cleaning equipment for semiconductor process control.

The Consolidated Fluorescence Microscopy Business Unit provides advanced optical fluorescence microscopy instruments with multi-photon, multipoint scanning confocal, miniature head-mount, 3D super-resolution, light-sheet modalities for studies in life science applications.

The Canopy Business Unit provides products and services to support the multi-omics needs of researchers in translational research, drug and biomarker discovery.

• Bruker Spatial Biology Division:

Provides the CosMx Spatial Molecular Imager and GeoMx Digital Spatial Profiler technologies for interrogating spatial transcriptomics, the nCounter technology for quantitation of gene expression, and the Cellscape technology for precision spatial proteomics.

These technologies allow researchers to elucidate gene and protein expression in a spatial context, which is useful for characterizing the underlying biology of organs and tissues, as well as for deriving deep biological insight into gene and protein expression for the development of biomarkers.

In addition, Bruker Spatial Biology offers a variety of services for transcriptional profiling and multiomic analysis, spanning the spectrum from early discovery research to translational research and clinical trials.

• The Consolidated Fluorescence Microscopy Business Unit:

Provides advanced optical fluorescence microscopy instruments with multi-photon, multipoint scanning confocal, miniature head-mount, 3D super-resolution, light-sheet modalities for studies in life science applications.

• The Bruker Cellular Analysis Business Unit:

Provides single-cell biology research tools to deliver deep insights into cellular function and new perspectives on phenomes and genotype-to-phenotype.

Customers of our BSI NANO Segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies, and other businesses involved in materials analysis.

During 2023, we launched several new products including D6 Phaser, TI 990, Infinite Focus G6, and NanoMet .

In October 2023 we acquired PhenomeX Inc., a functional cell biology company renamed Bruker Cellular Analysis or “BCA” that provides single-cell biology research tools to deliver deep insights into cellular function and new perspectives on phenomes and genotype-to-phenotype.

During 2024 we acquired substantially all of the assets and rights associated with NanoString Technologies, a leading provider of life-science research solutions for spatial transcriptomics and gene expression analysis.

We subsequently created the Bruker Spatial Biology division, as described above, consisting of NanoString Technologies and Canopy Biosciences, along with Bruker Spatial Genomics.

Furthermore, during 2024, we acquired Nion LLC, a manufacturer of innovative high-end scanning transmission electron microscopes, enhancing Bruker’s product offerings in materials science research and providing the technology base for applications in electron diffraction crystallography.

Subsequently the Nion operations were integrated into the Bruker AXS division.

The BSI NANO Segment systems are based on the following technology platforms:

7 unchanged sentences

• CS/ONH— Combustion analysis for carbon, sulfur, oxygen, nitrogen, and hydrogen in solids;

• STEM —scanning transmission electron microscopes

• AFM —Atomic force microscopy;

4 unchanged sentences

• Alicona —Focus variation optical technology for non-contact dimensional metrology;

• Canopy —Multiplexed fluorescence-based single cell imaging for suspended cells and tissues as well as multi-omics sample characterization;

• BCA —Optofluidic platforms and Proteomic Barcoding platforms;

• Canopy —Multiplexed fluorescence-based single cell imaging as well as multi-omics sample characterization;

• NanoString – platforms for spatial transcriptomic analysis and for the measurement of gene expression through detection of RNA abundance

XRD systems investigate polycrystalline samples or thin films with single wavelength X-rays.

7 unchanged sentences

The system collects the X-rays, and the software analyzes the resulting data to determine the elements that are present.

Our XRF products provide automated solutions on a turn-key basis for industrial users that require automated, controlled production processes that reduce product and process cost, increase output and improve product quality.

Our XRF products provide automated solutions on a turn-key basis for industrial users that require

automated, controlled production processes that reduce product and process cost, increase output and improve product quality.

Our XRF products cover substantially all of the periodic table and can analyze solid, powder or liquid samples.

28 unchanged sentences

Combustion and inert gas fusion analyzers are used for applications in metal production and processing, chemicals, ceramics and cement, coal processing, oil refining and semiconductors.

STEM provides atomic-resolution information about physical and electronic structure, chemical identity, and local bonding environments by passing an atom-sized beam of electrons through a sample.

The beam is raster scanned, and a series of different detectors are used to make atomic-resolutions maps showing atomic locations, chemical species, shifts in valence states, and even vibrational modes (phonons).

Our STEM systems are used primarily in academic and national lab settings for basic science, advancing our fundamental understanding of the materials that will drive the next generation of technologies such as batteries, computer chips, and quantum information.

AFM systems provide atomic or near-atomic resolution of material surface topography using a nano-scale probe that is brought into light contact with the sample being investigated.

5 unchanged sentences

Multipoint scanning confocal systems allow live cell imaging with rapid acquisition of images for structural and composition analysis.

Miniature head-mount microscopes allow monitoring of animal brain activity during free-roaming, naturalistic behavior at cellular level.

Miniature head-mount microscopes allow monitoring of animal brain activity during free-roaming, naturalistic

behavior at cellular level.

Super-resolution and single-molecule localization microscopy products allow imaging below the optical diffraction limit by an order of magnitude.

15 unchanged sentences

These technologies, along with Canopy’s more basic IHC and FISH services, allow researchers to elucidate gene and protein expression in a spatial context, which is useful for deep biological insight into gene expression and for the development of biomarkers.

Canopy also provides transcriptional profiling services covering a variety of assays, including RNASeq and qPCR.

Our multi-omic services provide data elucidating gene expression, signaling pathways, and differential expression trends on customer provided biological samples.

These services generally incorporate a data analysis service as well and can be utilized with multiple types of samples from very early discovery research through clinical trials.

Canopy also provides transcriptional and multi-omic profiling services covering a variety of assays, including RNASeq and qPCR.

BCA provides customers with, among other offerings, Optofluidic platforms such as the Beacon and Beacon Select as well as Proteomic Barcoding platforms, such as the IsoLight System and the IsoSpark System.

These platforms provide scientists with opportunities to perform cell biology research through experiments using our proprietary consumables.

The BEST Segment designs, manufactures and distributes superconducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.

Additionally, BEST develops, manufactures and markets sophisticated devices and complex tools based primarily on metallic low temperature superconductors that have applications in “big science” research, including radio frequency accelerator cavities and modules, power couplers and linear accelerators.

BEST also manufactures and sells non-superconducting high technology tools, such as synchrotron and beamline instrumentation, principally to customers engaged in materials research and “big science” research projects.

NanoString provides the CosMx Spatial Molecular Imager and GeoMx Digital Spatial Profiler for interrogating spatial transcriptomics;

and the nCounter Analysis System for quantitation of RNA-based gene expression.

These technologies allow researchers to measure gene expression in a spatial context at the regional and single-cell level, and to quantify RNA gene expression in a targeted manner, respectively.

Together, these tools are useful for characterizing the underlying biology of organs and tissues, the spatial gene expression associated with various disease states, and for deriving insights to drive the development of biomarkers.

The BEST Segment designs, manufactures and distributes superconducting materials, such as metallic low temperature superconductors (LTS) and high temperature superconductors (HTS), for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications in medical, clinical, pharmaceutical, high energy physics, renewable energy and environmental research.

BEST Segment offers a range of multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats, as well as customization to precise specifications for individual applications including radio frequency accelerator cavities and modules, power couplers and linear accelerators.

The Bruker Rod-Restack Process (RRP®) conductor portfolio is designed for fusion and high-energy physics applications that demand the highest magnetic fields.

The BEST Segment HTS solutions support high field and ultra-high field applications using round cross-section conductor design and solenoid applications for the electrical and healthcare industries.

Additionally, BEST designs and manufactures Cuponal which is an engineered alternative to copper wire and busbar.

Cuponal high conductivity copper-clad aluminum (CCA) retains all the surface properties of copper and provides a cost-effective and weight-saving alternative to solid copper primarily in the aerospace industry providing weight savings and improved fuel efficiency.

Sales and Marketing

1 unchanged sentence

We also utilize indirect sales channels to reach customers.

We have various international distributors, independent sales representatives and various other representatives in parts of Asia, Latin America, Africa, the Middle East and Eastern Europe.

We have various international distributors and independent sales representatives in parts of Asia, Latin America, Africa, the Middle East and Eastern Europe.

These entities augment our direct sales force and provide coverage in areas where we do not have direct sales personnel.

In addition, we have adopted a distribution business model in which we engage in strategic distribution alliances with other companies to address certain market segments.

The sales cycle for our products is dependent on the size and complexity of the system and budgeting cycles of our customers.

22 unchanged sentences

We believe that the principal competitive factors in our markets are technology-based applications expertise, product specifications, functionality, reliability, marketing expertise, distribution capability, proprietary patent portfolios and cost effectiveness.

BSI BioSpin Segment Competition

The BSI BioSpin Segment competes with companies that offer magnetic resonance spectrometers, mainly JEOL, QOne Instruments, Ciqtek, Magritek, Nanalysis and Oxford Instruments.

Our significant competitors (by segment) are as follows:

The BSI BioSpin Segment competes with companies that offer magnetic resonance spectrometers, mainly JEOL, QOne Instruments, Quad, Ciqtek, Magritek, Nanalysis and Oxford Instruments.

In the field of preclinical imaging, BioSpin competes with PerkinElmer Inc., Mediso, Trifoil, MR Solutions and others.

BSI CALID Segment Competition

The BSI CALID Segment competes with a variety of companies that offer mass spectrometry-based and molecular spectrometry-based systems.

4 unchanged sentences

CALID’s CBRNE detection customers are highly fragmented, and it competes with a number of companies in this area, of which the most significant competitor is Smiths Detection.

BSI Nano Segment Competition

The BSI NANO Segment competes with companies that offer analytical X-ray solutions, OES systems, AFM and SOM systems and optical fluorescence systems, primarily Rigaku, Oxford Instruments, Agilent, Thermo Fisher Scientific, Ametek’s Spectro and Edax divisions, PANalytical, Park Systems, Olympus, Nikon, Zeiss and Danaher’s Leica business.

BEST Segment Competition

BEST competes with Western Superconducting Technologies Co., Ltd.

3 unchanged sentences

Manufacturing and Suppliers

Several of our manufacturing facilities are certified under ISO 9001:2008 and ISO 13485, international quality standards.

Several of our manufacturing facilities are certified under ISO 9001:2008 international quality standards.

We manufacture and test our magnetic resonance products at our facilities in Faellanden, Switzerland;

1 unchanged sentence

and Karlsruhe, Germany.

We manufacture and test our preclinical imaging products at our facilities in Ettlingen and Leipzig, Germany;

We manufacture and test our preclinical imaging products at our facilities in Ettlingen, Germany;

Wissembourg, France;

1 unchanged sentence

and Faellanden, Switzerland.

We manufacture and test our automation solutions at our facility in Basel, Switzerland.

We manufacture and test our mass spectrometry products at our facilities in Bremen, Germany.

We principally manufacture and test our molecular spectroscopy products, including CBRNE detection products, at our facilities in Ettlingen, Germany.

We manufacture and test our X-ray, OES and AFM products at our facilities in Penang, Malaysia;

Karlsruhe and Berlin, Germany;

Santa Barbara, California, U.S.A.;

and Migdal HaEmek, Israel.

We principally manufacture and test our molecular spectroscopy products, including CBRNE detection products, at our facilities in Ettlingen, Leipzig and Erlangen, Germany as well as Mississauga, Canada, Wallisellen, Switzerland and Osaka, Japan.

We manufacture and test our X-Ray products at our facilities in Karlsruhe, Berlin and Geesthacht, Germany;

Migdal HaEmek, Israel;

Kontich, Belgium;

Kirkland, Washington, USA, and Penang, Malaysia.

Our S-OES products are manufactured at our sites in Karlsruhe, Germany and Penang, Malaysia.

AFM instruments and components are manufactured at Santa Barbara and Camarillo, California, USA;

Berlin, Germany;

and Penang, Malaysia.

We manufacture and test the majority of our energy and superconducting products at our facilities in Hanau, Germany;

7 unchanged sentences

We purchase materials and components from various suppliers that are either standard products or built to our specifications.

We obtain some of the components included in our products from a limited group of suppliers or from a single-source supplier for items such as charge coupled device area detectors, X-ray tubes, robotics, infrared optics and others.

We obtain some of the components included in our products from a limited group of suppliers or from a single-source supplier for items such as ceramics, charge coupled device area detectors, X-ray tubes, robotics, infrared optics and others.

BEST has an ongoing collaboration and a joint technology development agreement with Allegheny Technologies Incorporated to advance state-of-the-art niobium-based superconductors, including those used in MRI magnets for the medical industry, and preclinical MRI magnets used in the life-science tools industry.

6 unchanged sentences

The German government requires that we use, and market technology developed under grants in order to retain our rights to the technology.

We have also accepted some sponsored research contracts from private sources.

BSI BioSpin Segment Research and Development

We have also accepted some sponsored

research contracts from private sources.

Additionally, the Company has been able to gain access to research and development capabilities through acquisitions, acquiring the intellectual property, technology and expertise of the acquired companies.

Our significant research and development activities (by segment) are as follows:

BSI BioSpin Segment:

The research and development performed in the BSI BioSpin Segment is primarily conducted at our facilities in Ettlingen, Germany;

1 unchanged sentence

The BSI BioSpin Segment maintains technical competencies in core magnetic resonance technologies and single- and multimodal imaging technologies and capabilities, including NMR, EPR, MRI, MPI, PET and CT.

The most recent technological innovations included Bruker’s ultra-high-field class in the NMR and MRI product lines and the benchtop Fourier NMR platform.

The most recent technological innovations included Bruker’s ultra-high-field class (1GHz and above) in the NMR and MRI product lines and the benchtop Fourier NMR platform.

As part of our continuous development of systems and software, we have achieved major milestones in 2023 to make NMR and MRI technologies accessible to more labs, such as reduced siting requirements.

BSI CALID Segment Research and Development

The research and development performed in the BSI CALID Segment is primarily conducted at our facilities in Bremen and Ettlingen, Germany;

Faellanden, Switzerland and Wissembourg, France.

BSI CALID Segment:

The research and development performed in the BSI CALID Segment is primarily conducted at our facilities in Bremen, Ettlingen, Leipzig and Erlangen, Germany;

Faellanden and Wallisellen, Switzerland;

Toronto, Canada;

Osaka, Japan, Wissembourg, France;

Athens, Greece;

and Torino, Italy.

The BSI CALID Segment maintains technical competencies in core mass spectrometry technologies and capabilities, including:

MALDI, ESI and EI/CI ion source, TOF, TOF/TOF, ion traps, MRMS, quadrupole and IMS analyzers and bioinformatics.

Recent projects include the innovative timsTOF mass spectrometer for separation and analysis of unresolved compounds and conformations.

Recent projects include the innovative timsTOF mass spectrometer for separation and analysis of unresolved compounds and conformations and further enhanced instrument sensitivity.

In addition, new sample preparation and automation workflows were developed for deep plasma proteomics (Biognosys P2 workflow and Preomics ENRICHplus kit).

The BSI CALID Segment also maintains technical competencies in core vibrational spectroscopy technologies and capabilities, including FT-IR, NIR and Raman.

BSI Nano Segment Research and Development

BSI NANO Segment:

The research and development performed in the BSI NANO Segment is primarily conducted at our facilities in Karlsruhe, Berlin and Leipzig, Germany;

Penang, Malaysia;

Madison, Wisconsin, Eden Prairie, Minnesota, San Jose, Santa Barbara and Emeryville, California, and St.

Madison, Wisconsin, Eden Prairie, Minnesota, San Jose, Santa Barbara and Emeryville, California, Bothell, Washington, and St.

Louis, Missouri, U.S.A.

The BSI Nano Segment maintains technical competencies in core X-ray technologies and capabilities, including detectors used to sense X-ray and X-ray diffraction patterns, X-ray sources and optics that generate and focus the X-rays, robotics and sample handling equipment that holds and manipulates the experimental material, and software that generates

the structural data.

The BSI NANO Segment maintains technical competencies in core X-ray technologies and capabilities, including detectors used to sense X-ray and X-ray diffraction patterns, X-ray sources and optics that generate and focus the X-rays, robotics and sample handling equipment that holds and manipulates the experimental material, and software that generates the structural data.

Recent projects include fluorescence microscopy with simultaneous, all-optical stimulation and imaging platforms for optogenetics neuroscience research and light sheet cell microscopy systems, which enable brain research and high-resolution live cell research and single-cell biology research tools to deliver deep insights into cellular function and new perspectives on phenomes and genotype-to-phenotype linkages.

2 unchanged sentences

Recent innovations include elemental analyzer systems for advanced applications and research and simultaneous, all-optical stimulation and imaging platforms for neuroscience applications.

BEST Segment Research and Development

BEST Segment:

The research and development performed in the BEST Segment is primarily conducted at our facilities in Hanau and Bergisch Gladbach, Germany;

11 unchanged sentences

As a result, we cannot predict the enforceability of our patents with certainty.

In addition, we are aware of the existence from time to time of patents in certain countries, which, if valid, could impair our ability to manufacture and sell products in these countries.

In addition, we are

aware of the existence from time to time of patents in certain countries, which, if valid, could impair our ability to manufacture and sell products in these countries.

We also rely upon trade secrets, know-how, trademarks, copyright protection and licensing to develop and maintain our competitive position.

4 unchanged sentences

We are a party to various government contracts.

Under some of these government contracts, the government may receive license or similar rights to intellectual property developed under the contract.

Under some of these government contracts, the government may receive a license or similar rights to intellectual property developed under the contract.

However, under the government contracts we enter, we generally receive at least non-exclusive rights to any items or technologies we develop.

3 unchanged sentences

We do not expect this compliance to have a significant impact on our capital spending, earnings or competitive position.

Our products are subject to the U.S.

Certain of our products are subject to the U.S.

Food and Drug Administration’s, or the FDA’s, requirements for electronic radiation emitting products, which include requirements related to record-keeping and reporting;

4 unchanged sentences

If the FDA finds that the report is complete, it provides approval in the form of what is known as an accession number.

Bruker AXS may not market a product until it has received an accession number.

Bruker AXS may not market a product in the U.S.

until it has received an accession number.

In addition, Bruker AXS submits an annual report to the FDA that includes the radiation safety history of all products it sells in the United States.

4 unchanged sentences

Our Bruker AXS subsidiary possesses low-level radiation materials licenses from the local radiation safety authority, Gewerbeaufsichtsamt Karlsruhe, for its facility in Karlsruhe, Germany, and from the local radiation safety authority, Kanagawa Prefecture, for its facility in Yokohama, Japan, as well as from various other countries in which it sells its products.

Our Bruker Daltonics subsidiary possesses low-level radiation licenses for facilities in Billerica, Massachusetts and Leipzig, Germany.

Our Bruker Optics subsidiary possesses low-level radiation licenses for facilities in Billerica, Massachusetts and Ettlingen and Leipzig, Germany.

Nuclear Regulatory Commission also has regulations concerning the exposure of our employees to radiation.

Certain of our clinical products are subject to regulation as medical devices in the United States by the FDA and by similar regulatory bodies in other countries where such products are sold.

Certain of our products are subject to regulation as medical devices in the United States by the FDA and by similar regulatory bodies in other countries where such products are sold.

The regulatory requirements imposed by the FDA and other regulatory bodies govern a wide variety of product-related activities, from quality management, design and development to labeling, manufacturing, promotion, sales, and distribution.

6 unchanged sentences

Should we pursue an FDA or comparable foreign regulatory authority clearance, authorization, or approval for a new device or device modification, we cannot be certain that we will receive required clearance, authorization, or approval on a timely basis or at all.

The failure to receive clearance, authorization, or approval for significant new products or modifications to existing products on a timely basis or at all could have a material, adverse effect on our financial condition and results of operations.

The failure to receive clearance, authorization, or approval for

significant new products or modifications to existing products on a timely basis or at all could have a material, adverse effect on our financial condition and results of operations.

Both before and after a medical device product is commercially released, we have ongoing responsibilities under FDA and foreign regulations.

5 unchanged sentences

The FDA and comparable foreign regulatory authorities may take enforcement action against us, should the FDA determine we have engaged in “off-label” promotion or other violative marketing activities.

In addition, FDA and comparable foreign regulatory authorities may take enforcement action should they determine that we have marketed any of our other (non-medical device) products for FDA-regulated purposes without obtaining the required regulatory clearances, authorizations, or approvals or ensuring such products comply with other FDA and comparable foreign regulatory requirements.

The European Union Directive 98/97/EC (IVDD) was replaced by the Regulation (EU) 2017/746 of April 5, 2017, on in vitro diagnostic medical devices (IVDR).

7 unchanged sentences

Total remaining performance obligations as of December 31, 2024, and 2023 was approximately $2,090.4 million and $2,226.7 million, respectively.

The modest decrease in our backlog in 2023 compared to 2022 was primarily driven by lower BEST order bookings as of December 31, 2023.

The decrease in our backlog in 2024 compared to 2023 was primarily driven by lower BEST order bookings.

We generally experience varying revenue levels in the first three quarters of the year, while our fourth quarter revenues have historically been stronger than the rest of the year.

As a result, backlog on any particular date can be indicative of our short-term revenue performance but is not necessarily a reliable indicator of long-term revenue performance.

As a result, backlog on any particular date is not necessarily a reliable indicator of long-term revenue performance.

Human Capital

3 unchanged sentences

Further, we strive to create a work environment that promotes integrity, respect and trust among our employees.

As of December 31, 2023, and 2022, we had 9,707 and 8,525 full-time employees worldwide, respectively, of which 1,792 and 1,410, respectively, were located in the United States.

Our senior leadership team is 80% male and 20% female.

The table below provides our employees by functional area.

Workforce Composition

As of December 31, 2024, and 2023, Bruker employed the following full-time employees:

Number of Employees

Production and distribution

Selling and marketing

General and administrative

Research and development

Diversity, Talent Retention and Development

Bruker has initiatives and programs to attract, develop and retain our talent tailored to specific employee populations and geographies, including leadership development programs, technical training, and other skill-based training.

Several leadership development programs are in place for global groups and functions where competency-based performance assessments are completed annually to identify employees who qualify as high performers and high potentials for advancement into key leadership positions.

These individuals are provided with additional skill, mentoring, and project opportunities to strengthen their capabilities for career advancement as future successors across the organization.

Bruker has established a customized development program for talent providing them with an opportunity to develop their leadership skills over a period of 12 months by attending different modules, which are run in a hybrid format.

Each participant is supported by a mentor during the program to facilitate their learning and advance their development.

In 2023, Bruker further expanded its online learning platform designed to support employee development.

Bruker identified areas of growth opportunity through increased education and created specific training paths to support employee technical skill development.

Learning modules were also integrated into quarterly training sessions to facilitate learning and knowledge sharing among users.

Full-time employees in the United States

Full-time employees in other countries

Total employees

The table below provides a breakdown of Bruker’s employees by functional area.

Number of Employees

Production and distribution employees

Selling and marketing employees

General and administrative employees

Research and development employees

Total employees

Talent, Development and Workforce Strategy

Bruker is committed to providing a variety of learning opportunities to advance the personal and professional goals of our global teams.

Our talent and development programs cover a variety of topics including those focused on technical expertise, leadership and communication skills.

A global performance management process promotes regular feedback and coaching by managers to develop employees.

Throughout the year, managers and employees engage in annual objective setting, mid-year reviews of performance as well as a year-end performance evaluation.

Managers and employees participate in career goal conversations throughout the year.

Managers and employees also participate in career conversations throughout the year.

These discussions are critical tools that reinforce the alignment of employee activities and career goals throughout the year and provide employees opportunities to grow.

Several talent assessment tools are used to support this dialogue and achieve career development goals.

Bruker continues to focus on employer branding initiatives to further improve visibility and attractiveness for potential candidates.

In 2023 this included participation in local, regional and international career events providing an opportunity to engage with candidates about the innovative and exciting opportunities Bruker offers.

Enhancing partnership with organizations including colleges and universities also increases awareness of Bruker.

Bruker is focused on promoting diversity across our organization.

Bruker employees come from diverse backgrounds all over the world and are united by a shared purpose—innovation with integrity.

The work performed every day at Bruker inspires and impacts global scientific research—and diverse and dynamic teams inspire each other to achieve their full potential.

Cross-functional teams collaborate and enable the creation of new ideas by actively identifying and recruiting talent with diverse professional experiences, skills and backgrounds including from diverse gender, racial and ethnic backgrounds.

Several initiatives support increasing diversity and inclusion at Bruker.

These programs support Bruker’s desire for a diverse workforce and support the talent attraction and development of all employees at Bruker, regardless of their gender.

In the context of celebrating diversity across Bruker, employees engage in initiatives which support all genders in the workplace.

Bruker male and female employees play active roles in these initiatives, which exhibit our commitment to inclusion.

Germany’s nationwide Girls’ Day continues to be popular among girls ages 10 and older to support their career and educational aspirations and accomplishments.

Additionally, Bruker participated in several Women’s Day celebration events across the globe, including a gathering of Bruker women in China.

Events such as these provide opportunities for connection among colleagues and foster a sense of togetherness which

supports employees of all genders in the workplace.

A program called Coffee Buddies has been popular in recent years at Bruker in Germany and has begun to expand to other countries.

These programs offer positive connections for new hires, establishing internal networks across functions for employees who may not otherwise have opportunity to interact.

Events and connection opportunities are important to foster a diverse and inclusive environment, but training is also highly important.

In 2023, Bruker talent acquisition professionals participated in an Unconscious Bias course which increases self-awareness of personal biases.

This training program is highly important to support fairness in the recruitment, evaluation and decision making processes that drive talent acquisition and the development of employees.

Performance assessments also support the identification of our high performers and high potential employees based on merit.

These employees are encouraged to continue their professional development with additional coaching and on the job learning opportunities to enhance their readiness for future advancement.

In 2024, we continued with our supervisor training program for newly hired or promoted first line leadership.

This program is expanding to other employee groups within Bruker to provide a consistent foundation of knowledge and expectations for our leaders.

Additionally, our robust leadership program brings together participants from across the globe to provide education aimed to enhance their skills in business acumen, leadership, and communication.

A practical opportunity to apply these skills is included as part of the program under the mentorship of experienced leaders.

The coaching from internal leaders is supported also by professional external mentorship ensuring a comprehensive learning experience.

Employee Engagement

Bruker is committed to fostering a culture of continuous learning and knowledge sharing to support development and retention, and also recognizes the importance of inclusion.

Inclusion is an essential element of our core values and is crucial to the dynamic, entrepreneurial working environment our employees thrive in, and aligns with our mission to innovate responsibly and with integrity.

We support several initiatives that promote inclusion at Bruker:

• Cross-functional collaboration and teamwork, encouraging employees to build relationships across different business units and geographies.

• Employee engagement programs, including professional networking opportunities, internal mentorship, and knowledge sharing platforms.

• Global team-building events, providing employees with opportunities to interact and strengthen connections.

Our employees play active roles in these initiatives, often creating and facilitating them directly.

Bruker has continued to support events such as Germany’s nationwide Girls’ Day and celebration of the festival of colors, HOLI, in India.

These programs and events help employees develop their skills, expand their networks, and contribute meaningfully to our business objectives.

They also provide critical connections for new hires and establish internal networks across functions for employees who may not otherwise have opportunity to interact.

Employee Health and Safety

Ensuring the safety and wellbeing of our employees is a top priority for Bruker.

We accomplish this through compliance with applicable laws and regulations regarding workplace safety, including recognition and control of workplace hazards, the elimination of unsafe manufacturing and workplace practices, tracking injury and illness rates, utilizing a global travel health program and maintaining detailed emergency and disaster recovery plans.

We are committed to reducing safety risks across business units and at our corporate and manufacturing sites worldwide.

Bruker prioritizes the safety and wellbeing of its employees.

Bruker accomplishes this through compliance with applicable laws and regulations regarding workplace safety, including recognition and control of workplace hazards, the elimination of unsafe manufacturing and workplace practices, tracking injury and illness rates, utilizing a global travel health program and maintaining detailed emergency and disaster recovery plans.

We are committed to reducing safety risks across our business groups and at our

corporate and manufacturing sites worldwide.

The following are examples of initiatives and programs designed with employee health and safety in mind:

• In the United States, Bruker established a wellness program that includes regular communications to promote initiatives, challenges and specialized webinars designed to improve Bruker employees’ physical, emotional, social, and financial health.

In 2023, a wellness platform was introduced that offers a comprehensive opportunity for learning, links to resources such as the Employee Assistance Program, financial planning and benefits as well as incentivized activity competitions.

• Our sites around the globe are mindful about safety and ready to make adjustments, as needed.

One Bruker site, for example, after recognizing an increase in muscle pain with production teams, started encouraging employees in each production shift to stretch and do light exercise to prepare them for their work in order to reduce the likelihood of muscle strain.

• A program called “Caught Doing the Right Thing” is a safety and quality recognition program for hourly employees.

The focus of the program is to recognize employees who demonstrate correct behaviors with respect to safety and quality.

This has encouraged active engagement from employees and a renewed focus on personal and team safety.

• One of our German facilities has a robust accident prevention program and contributes to active environmental protection.

This has been recognized with an ISO 45001 certification.

• A confidential Employee Assistance Program has been implemented at several new sites providing no-cost support to employees and offering assistance on several personal topic areas.

• Many locations throughout the globe encourage employees to be mindful of a healthy lifestyle such as organized group exercise activities.

These activities not only enhance employee physical health, but emotional and mental health as well through increasing camaraderie among colleagues.

Available Information

5 unchanged sentences

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1. Business